Better Therapeutics Inc (BTTX) USD0.001

Sell:$0.00Buy:$0.00No change

Prices delayed by at least 15 minutes
Sell:$0.00
Buy:$0.00
Change:No change
Prices delayed by at least 15 minutes
Sell:$0.00
Buy:$0.00
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

Better Therapeutics, Inc. is a prescription digital therapeutics (PDT) company, which is engaged in developing a software-based novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases (CMDx). Its platform allows for the creation of multiple PDTs that are designed to treat patients with CBT, delivered digitally via an app, to address the underlying causes of CMDx. Its lead PDT product candidate, AspyreRx, is a digital behavioral therapeutic delivering CBT for the treatment of a cardiometabolic disease. AspyreRx is a prescription-only digital treatment indicated to provide cognitive behavioral therapy to patients 18 years or older with T2D. The device targets behavior to aid in the treatment of T2D. Its pipeline also includes programs for the treatment of hypertension, hyperlipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH) and chronic kidney disease.

Key people

Craig R. Jalbert
President, Chief Executive Officer, Treasurer, Company Secretary, Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US08773T1043
  • Market cap
    $4,990.00
  • Employees
    54
  • Shares in issue
    49.86m
  • Exchange
    Over The Counter
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.